TY - JOUR
T1 - miR-181a/b therapy in lung cancer
T2 - reality or myth?
AU - Braicu, Cornelia
AU - Gulei, Diana
AU - Cojocneanu, Roxana
AU - Raduly, Lajos
AU - Jurj, Ancuta
AU - Knutsen, Erik
AU - Calin, George Adrian
AU - Berindan-Neagoe, Ioana
N1 - Funding Information:
Work in Dr. Berindan-Neagoe’s laboratory was supported by a POC Grant, Competitively Operational Program, 2014–2020, no. 35/01.09.2016, MySMIS 103375 (CANTEMIR). Dr. Calin is the Felix L. Haas Endowed Professor in Basic Science. Work in Dr. Calin’s laboratory is supported by National Institutes of Health (NIH/ NCATS) grant UH3TR00943-01 through the NIH Common Fund, Office of Strategic Coordination (OSC), NCI grants 1R01 CA182905-01 and 1R01CA222007-01A1, an NIGMS 1R01GM122775-01 grant, a U54 grant #CA096297/CA096300 – UPR/MDACC Partnership for Excellence in Cancer Research 2016 Pilot Project, a Team DOD (CA160445P1) grant, a Chronic Lymphocytic Leukemia Moonshot Flagship project, a Sister Institution Network Fund (SINF) 2017 grant, and the Estate of C. G. Johnson, Jr.
Publisher Copyright:
© 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
PY - 2019/1
Y1 - 2019/1
N2 - Despite substantial progress in oncology, lung cancer remains the number one malignancy in terms of both incidence and mortality rates, and there thus remains an urgent need for new therapeutic alternatives. MicroRNA (miRNA) have an important role in cancer initiation and progression due to their capacity to interfere with transcriptional signaling and regulate key cellular processes. miR-181a and miR-181b (miR-181a/b), which are located on chromosomes 1 and 9, are pathologically expressed in the tumor tissue and plasma of patients diagnosed with lung cancer. The miR-181a/b regulatory mechanisms are sophisticated and are directly related to different target genes. In recent years, an ever-increasing number of studies have focused on the biological relevance of miR-181a/b in key cellular processes. In this paper, we aim to discuss the challenging experimental data related to miR-181a/b and their potential use for the development of new therapeutic approaches in lung cancer. We will further present the ongoing issues regarding the regulation of their multiple target genes, and their potential use as biomarkers and therapeutic targets in this deadly malignancy.
AB - Despite substantial progress in oncology, lung cancer remains the number one malignancy in terms of both incidence and mortality rates, and there thus remains an urgent need for new therapeutic alternatives. MicroRNA (miRNA) have an important role in cancer initiation and progression due to their capacity to interfere with transcriptional signaling and regulate key cellular processes. miR-181a and miR-181b (miR-181a/b), which are located on chromosomes 1 and 9, are pathologically expressed in the tumor tissue and plasma of patients diagnosed with lung cancer. The miR-181a/b regulatory mechanisms are sophisticated and are directly related to different target genes. In recent years, an ever-increasing number of studies have focused on the biological relevance of miR-181a/b in key cellular processes. In this paper, we aim to discuss the challenging experimental data related to miR-181a/b and their potential use for the development of new therapeutic approaches in lung cancer. We will further present the ongoing issues regarding the regulation of their multiple target genes, and their potential use as biomarkers and therapeutic targets in this deadly malignancy.
KW - lung cancer
KW - miR-181a/b
KW - therapy
UR - http://www.scopus.com/inward/record.url?scp=85059495188&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059495188&partnerID=8YFLogxK
U2 - 10.1002/1878-0261.12420
DO - 10.1002/1878-0261.12420
M3 - Review article
C2 - 30548184
AN - SCOPUS:85059495188
SN - 1574-7891
VL - 13
SP - 9
EP - 25
JO - Molecular oncology
JF - Molecular oncology
IS - 1
ER -